ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03433807
Expanded Access Status : Available
First Posted : February 15, 2018
Last Update Posted : July 17, 2018
Sponsor:
Information provided by (Responsible Party):
Santhera Pharmaceuticals

February 8, 2018
February 15, 2018
July 17, 2018
 
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)
The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.
Not Provided
Expanded Access
Intermediate-size Population
Drug: Idebenone
900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Available
Contact: John Karafilidis, PharmD 978-427-7102 John.Karafilidis@santhera.com
United States
 
 
NCT03433807
Santhera Pharmaceuticals
Santhera Pharmaceuticals
Not Provided
Not Provided
Santhera Pharmaceuticals
July 2018